ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.386
-0.007 (-1.88%)
At close: 3:38PM EST
Stock chart is not supported by your current browser
Previous Close0.393
Open0.398
Bid0.000 x 3000
Ask0.500 x 2200
Day's Range0.386 - 0.400
52 Week Range0.360 - 1.220
Volume236,781
Avg. Volume441,167
Market Cap25.99M
Beta (3Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.122
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.10
Trade prices are not sourced from all markets
  • IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
    Zacks7 days ago

    IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates

    IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -9.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press7 days ago

    IsoRay: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Richland, Washington-based company said it had a loss of 2 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of ...

  • GlobeNewswire8 days ago

    IsoRay Announces First Quarter Fiscal 2019 Financial Results

    Year Over Year First Quarter Revenues Increased 29%Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter RICHLAND, Wash., Nov. 08, 2018 -- IsoRay, Inc..

  • GlobeNewswire23 days ago

    IsoRay To Announce First Quarter Fiscal 2019 Financial Results on November 8, 2018

    IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2019 ended September 30, 2018 on Thursday, November 8, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal 2019 after the close of the U.S. stock markets on November 8, 2018.

  • Associated Press2 months ago

    IsoRay: Fiscal 4Q Earnings Snapshot

    On a per-share basis, the Richland, Washington-based company said it had a loss of 4 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. For the year, the company ...

  • GlobeNewswire2 months ago

    IsoRay Announces Fourth Quarter and Full-Year 2018 Financial Results

    Year over year fourth quarter revenues increased 17%Sixth Consecutive Quarter of Year-Over-Year Revenue IncreasesFull year revenues increased 24% RICHLAND, Wash., Sept. 25,.

  • When Can We Expect A Profit From IsoRay Inc (NYSEMKT:ISR)?
    Simply Wall St.2 months ago

    When Can We Expect A Profit From IsoRay Inc (NYSEMKT:ISR)?

    IsoRay Inc’s (NYSEMKT:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • GlobeNewswire2 months ago

    IsoRay To Announce Fourth Quarter and Year End 2018 Financial Results on September 25, 2018

    IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2018 on Tuesday, September 25, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2018 after the close of the U.S. stock markets on September 25, 2018. To listen to the conference call, please dial (877) 407-8031.

  • What You Must Know About IsoRay Inc’s (NYSEMKT:ISR) Financial Strength
    Simply Wall St.2 months ago

    What You Must Know About IsoRay Inc’s (NYSEMKT:ISR) Financial Strength

    The direct benefit for IsoRay Inc (NYSEMKT:ISR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...

  • ACCESSWIRE4 months ago

    Free Technical Research on IsoRay and Three More Medical Supplies Equities

    On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Staffing 360 Solutions and IsoRay

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.

  • IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy
    Market Realist4 months ago

    IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy

    Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44. IsoRay’s stock price was triggered by buoyed investor sentiment on the news of the FDA 510(k) clearance for the company’s GammaTile therapy for the treatment of recurrent brain tumors.

  • ACCESSWIRE6 months ago

    IsoRay to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...

  • When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?
    Simply Wall St.6 months ago

    When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?

    IsoRay Inc’s (AMEX:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • ACCESSWIRE6 months ago

    IsoRay, Inc. Discusses Competitive Landscape, FDA Clearance for New Product Line and Growth Drivers in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Tom LaVoy, Chairman of the Board & CEO of IsoRay, Inc. ...

  • Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately
    Simply Wall St.6 months ago

    Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately

    For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at IsoRay Inc’sRead More...